Genmab A/S
Every calculator, already run for GMAB
Open the full toolkit →You have the numbers on GMAB. Get the argument.
A written report on which of these readings actually decide the outcome for Genmab A/S, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering GMABAnalyst Price Target Disagreement for Genmab A/S
Wall Street's bull case implies +30% from the current price; the bear case implies -8%. A 37% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for GMAB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab…
GMAB — frequently asked
Is GMAB a buy right now?
Wall Street's consensus rating on Genmab A/S is Strong Buy across 12 analysts, with a mean price target of $39.14 (+13% vs. the current $34.74). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is GMAB overvalued?
GMAB trades at 27.6x trailing earnings, against a DCF fair value of $42 per share. The current price implies 4% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is GMAB's next earnings date?
Genmab A/S is next scheduled to report earnings around Nov 5, 2026. A full GMAB research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Genmab A/S?
Analysts covering Genmab A/S (GMAB) range from a bear-case target of $32.00 to a bull-case high of $45.00, with a mean consensus target of $39.14 across 11 analysts. The spread of $13.00 (37% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Genmab A/S against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Genmab A/S
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GMAB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Genmab A/S, in minutes. 3 free reports included with every account — no credit card required.